NeOnc Technologies

NeOnc Technologies is a multi-Phase 2 clinical-stage biopharmaceutical company with a mission to revolutionize the treatment of brain cancers and CNS diseases by overcoming the fundamental challenge of the Blood-Brain Barrier. The company's core innovation is a proprietary intranasal delivery platform, anchored by its clinical-grade Perillyl Alcohol (POH) synthesis, which transports therapeutics directly to the brain via cranial nerve pathways. Its strategy encompasses developing proprietary drug candidates (NEO100, NEO212) while positioning its platform as an enabling technology for partnerships. Recent achievements include a strategic PIPE financing led by Cinctive Capital and the presentation of Phase 1 data for its oral NEO212 program.

Proprietary intranasal delivery platform designed to transport therapeutics directly to the brain via olfactory/trigeminal nerve pathways, bypassing the Blood-Brain Barrier. Its cornerstone is a clinical-grade synthesis of Perillyl Alcohol (POH).

NeOnc competes with other late-stage GBM therapy developers (e.g., Kazia, Denovo) and BBB modulation platforms (e.g., focused ultrasound, receptor-mediated transport). Its key differentiators are the non-invasive, direct nose-to-brain delivery route and the dual therapeutic/enabling profile of its POH-based platform.